DelveInsight’s “Postpartum Depression Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Postpartum Depression, historical and forecasted epidemiology as well as the Postpartum Depression market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Explore the intricate details of the Postpartum Depression Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Postpartum Depression Market Forecast. Click here to stay ahead in healthcare innovation @ Postpartum Depression Market Size

Key Takeaways from the Postpartum Depression Market Report

• May 2024:- Interdisciplinary Center Herzliya– A Brief Relationship-Based Intervention for Post-Partum Depression; Effects on Mother’s Hormones, Depression and Parenting and on Infant Social-Emotional Development. A short term dyadic psychotherapy intervention for mothers with Post-Partum depression and their babies in the first year of life was developed.
• May 2024:- Medical University of South Carolina– An Open Label Study to Assess the Feasibility and Tolerability of Accelerated Theta Burst Repetitive Transcranial Magnetic Stimulation (iTBS-rTMS) for the Treatment of Post-Partum Depression.
• May 2024:- CHU de Reims- The peripartum period is the period between the last month of pregnancy and up to a year after childbirth. It can be considered a difficult time for women, as it is a period of transition during which vulnerability to psychiatric disorders and in particular to major depressive disorder (MDD) (Vesga-Lopez, Blanco, Olfson, Grant & Hasin, 2008).
• According to DelveInsight’s analysis, PPD majorly affects females but a small proportion of males can also experience depression post-pregnancy
• The total diagnosed prevalent population of Postpartum Depression in the 7 major markets was found to be 1,155,349 in 2020. In case of Postpartum Depression patients in the United States, the diagnosed prevalent cases were found to be 620,944 in 2020, which is expected to increase by 2032.
• In the EU5 countries the diagnosed prevalence of Postpartum Depression was found to be maximum in France with 99,815 cases, followed by the United Kingdom with 99,520 cases in2020. While, the least number of cases were found in Spain, i.e., 57,396 in 2020.
• The leading Postpartum Depression Companies such as Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, and others.
• Promising Postpartum Depression Therapies such as Citalopram, SAGE-217, Ketamine 0.5 mg/kg, and others.

Delve deep into the Postpartum Depression Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Postpartum Depression Market Forecast. Click here to shape the future @ Postpartum Depression Epidemiology Insights

Postpartum Depression Overview

Postpartum depression (PPD) is the most common non-psychotic, complication of childbearing affecting approximately 10-15% of women and as such, represents a considerable public health problem affecting women and their families. The postnatal period is well established as an increased time of risk for the development of serious mood disorders. There are three common forms of postpartum affective illness: the blues (baby blues, maternity blues), postpartum (or postnatal) depression, and puerperal (postpartum or postnatal) psychosis each of which differs in its prevalence, clinical presentation, and management.

Postpartum Depression Epidemiology Insights

• Total Diagnosed Prevalent Population
• Type-specific Diagnosed Prevalence

Navigate the complexities of the Postpartum Depression Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Postpartum Depression Market Forecast. Click here to get more insights @ Postpartum Depression Treatment Market

Postpartum Depression Market Insights

Antidepressant medications, cognitive-behavioral therapy (CBT), and interpersonal therapy are effective in the treatment of PPD. Other treatments which may be useful include psychodynamic therapy, light therapy, exercise, and yoga, but the current research evidence about the efficacy of such treatment regimens is more preliminary. Antidepressants, such as Abilify (aripiprazole), Zoloft (sertraline hydrochloride), Spravato (esketamine), Prozac (fluoxetine capsules), Celexa (citalopram hydrobromide), Luvox CR(Fluvoxamine Maleate) and Paxil CR (paroxetine) form the mainstay drug treatment for PPD. Although these drugs are approved for treating depression related disorders such as major depressive disorder (MDD), obsessive compulsive disorder (OCD), post – traumatic stress disorder (PTSD),treatment-resistant depression (TRD), etc., but they are being used as off-label drugs for the Postpartum Depression treatment.

Postpartum Depression Drug Market

The majorly used current therapeutic classes for treating PPD include Selective serotonin reuptake inhibitors (SSRIs), Serotonin non-epinephrine reuptake inhibitors (SRNIs), Atypical anti-depressants and Anti-psychotics Combination therapies (SSRIs and SRNIs). Expected Launch of potential therapies may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of Postpartum Depression. Owing to the positive outcomes of the few products during the developmental stage by key players such as Sage Therapeutics and others, the market is expected to witness a significant positive shift in the Postpartum Depression Market Size

Postpartum Depression Market Dynamics

The dynamics of Postpartum Depression (PPD) market is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise of efficient treatment options. The launch of emerging therapies is expected during the forecast period of 2024-2034.

Postpartum Depression Drugs Uptake

• Zuranolone (SAGE-217) by Sage Therapeutics is an investigational, oral, novel medicine in development for postpartum depression. It is given once-daily; a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders including PPD, major depressive disorder (MDD), and treatment-resistant depression. The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), which contributes in regulating CNS function significantly. SAGE-217 has been optimized for selectivity to synaptic and extrasynaptic type A γ-aminobutyric acid (GABAA ) receptors and a pharmacokinetic profile that is intended for daily oral dosing. The drug is being study in NEST program for PPD, under this one phase III (ROBIN Study; NCT02978326; 30 mg dose) is completed and second study (SKYLARK study; NCT04442503; 50 mg dose) is recruiting. The results from Robin study had shown a statistically significant improvement of 17.8 points in the Hamilton Rating Scale for Depression (HAMD-17) score, compared to 13.6 for placebo (primary endpoint, p = 0.0029), with statistically significant reductions in HAMD-17 compared to placebo maintained through the end of the four-week follow-up.
• Brii Biosciences is developing BRII-296, a GABAA PAM, for treating PPD. The company started the phase I trial in April 2021 and expects to start phase III trial in H1 2022 and a trial for PPD prevention is under consideration. The topline data readout for Phase I study was expected in 4Q 2021.
• Lipocine’s LPCN1154 Is an oral neuron-steroid being developed for the treatment of PPD. The drug is expected to be an “at home” treatment with easier treatment access than the current standard of care invasive option that requires hospitalization with significant limitations. Moreover, LPCN 1154 is expected to provide the required level of privacy for a mother, avoiding bonding/breast feeding interruptions due to the required hospitalizations for the current option. The company has completed a phase I PK study to assess dose proportionality with LPCN 1154 in which dose proportionality was observed and phase II trial is in progress, as per the company’s pipeline, as the US FDA had cleared the Investigational New Drug Application to initiate a Phase II study to evaluate the therapeutic potential of LPCN 1154 for the treatment of PPD in adults.

Unlock insights into the Postpartum Depression Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Postpartum Depression Market Forecast. Click here @ Postpartum Depression Market Drivers and Barriers

Scope of the Postpartum Depression Market Report

• Coverage- 7MM
• Study Period- 2024-2034
• Postpartum Depression Companies- Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, and others.
• Postpartum Depression Therapies- Citalopram, SAGE-217, Ketamine 0.5 mg/kg, and others.
• Postpartum Depression Market Dynamics: Postpartum Depression Market drivers and Postpartum Depression Market Barriers
• Postpartum Depression Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Postpartum Depression Unmet Needs, KOL’s views, Analyst’s views, Postpartum Depression Market Access and Reimbursement

Gain a strategic edge in the Postpartum Depression Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Postpartum Depression Market Forecast. Click here to lead in advancements @ Postpartum Depression Clinical Trials Assessment

Table of Content

1. Key Insights

2. Report Introduction

3. Postpartum Depression Market Overview at a Glance

4 Executive Summary of Postpartum Depression

5 Key events

6 Disease Background and Overview

7 Treatment and Management

8 Methodology

9 Epidemiology and Patient Population

10 Patient Journey

11 Marketed Therapies

12 Emerging Therapies

13 Postpartum Depression (PPD): Seven Major Market Analysis

14 KOL Views

15 SWOT Analysis

16 Unmet Needs

17 Market Access and Reimbursement

18 Appendix

19 DelveInsight Capabilities

20 Disclaimer

21 About DelveInsight

  

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/